Johnson & Johnson CEO Joaquin Duato States No Current Plans to Enter Weight-Loss Drug Market, Focus Remains on Neuroscience and Oncology Expansion

Johnson & Johnson CEO Joaquin Duato said on December 5 at the company’s investor day event that the company currently has no plans to produce weight-loss drugs, as the competition in this market has become overly intense. Duato stated that Johnson & Johnson is focused on expanding broadly in areas such as neurology and oncology. Duato added, "If Johnson & Johnson has the opportunity to stand out in the weight-loss drug market through assets that complement the company's business, it might reconsider." (Jiemian)Original Link